IL1B and diabetes mellitus: Given the role of interleukin-1β (IL-1β) in the inflammation associated with type 2 DM, anti-IL-1 therapies such as anakinra, canakinumab and gevokizumab are being investigated in both experimental models of DM and clinical trials.